Search results
Added:
2 months ago
Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute, Kansas City, US) and Dr Pasquale Santangeli (Cleveland Clinic, Cleveland, OH, US) discuss evidence-based strategies for preventing complications during complex atrial fibrillation and ventricular tachycardia ablation procedures.This expert discussion focuses on safety considerations in high-risk electrophysiology procedures, comparing…
View more
Added:
11 months ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE…
View more
Added:
1 year ago
Outcomes from a new CV disease risk assessment tool show significant improvements in CV, kidney and metabolic health after bariatric surgery. The study also found a reduction in estimated 10 year risk of developing total CV disease and a reduction in the risk of developing heart failure one year after bariatric surgery.In this short interview, Dr Danxia Yu (Vanderbilt University Medical Center,…
View more
Added:
11 months ago
Added:
5 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Added:
2 days ago
Source:
Radcliffe CVRM
High-sensitivity C-reactive protein (hsCRP), a marker of inflammation, has a debated role in primary cardiovascular (CV) prevention. A large, population-based study using UK Biobank data has provided further insight into its utility as a clinical biomarker for identifying individuals at residual risk who do not have known atherosclerotic cardiovascular disease (ASCVD).¹MethodologyThis population…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 - Dr Clyde Yancy (Northwestern University, US) joins us to explore the future trajectory of heart failure management, examining how prevention strategies, precision medicine approaches, and the evolving responsibilities of cardiologists are reshaping patient outcomes.Interview Questions:Looking at the current state of heart failure management, what do you see as the…
View more
Added:
1 year ago
ESC Congress 2024 — Improved patient-level adherence to guideline recommendations on heart rhythm control through healthcare professional education in patients with atrial fibrillation.Investigator, Dr Dipak Kotecha (University of Birmingham, UK) joins us in London to share key findings from the STEEER-AF study (NCT04396418).This prospective, cluster-randomized international study compared two…
View more
Start date:
Apr 03, 2025
End date:
Apr 05, 2025
Dates: April 3-5, 2025Location: Milan, ItalyTheme: "Risk Factor Realities in 2025"ESC Preventive Cardiology 2025 is the premier annual congress of the European Association of Preventive Cardiology (EAPC), bringing together the leading community of healthcare professionals dedicated to cardiovascular disease prevention.The 2025 Milan congress offers an unparalleled opportunity to engage with the…
View more
ESC 25: The HI-PRO Trial
Added:
7 months ago
Video